TP53 and B-cell chronic lymphocytic leukemia: From a clinical standpoint, BIRC3 lesions contribute to clinical aggressiveness and fludarabine refractoriness in CLL.15 Indeed, BIRC3 lesions identify a subgroup of CLL displaying poor survival (median 3.1 years) similar to that associated with TP53 abnormalities.15